Infectious

Infectious-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View Download All PDFs List View Archive

loading
Dosage and administration of non-fucosylated anti-cd40 antibodies
Seattle Genetics, Inc.
May 18, 2017 - N°20170137528

This invention relates methods of using a non-fucosylated anti-cd40 antibody for treatment of cancer and chronic infectious diseases.
Ctla4 binders
Seattle Genetics, Inc.
May 18, 2017 - N°20170137521

The present invention provides molecules, such as isvds and nanobodies, that bind to ctla4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules ...
Pd1/ctla4 binders
Seattle Genetics, Inc.
May 18, 2017 - N°20170137520

The present invention provides multispecific molecules, e. G., comprising more than one isvd or nanobody, that bind to pd1 and ctla4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease ...
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Antibodies to il-15
Calypso Biotech Sa
May 18, 2017 - N°20170137511

The present invention relates to antibodies binding il-15, in particular humanized antibodies. In particular, the anti-il-15 antibodies according to the invention are able to neutralize il-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or ...
System for implanting, activating, and operating an implantable battery
Ortho-ion Ltd.
May 18, 2017 - N°20170136236

Apparatus, systems, and methods for the treatment of bone, cartilage and other types of hard tissue. The treatments, which are suitable for extended treatment, include the treatment and prevention of pathologies through the controllable use of silver, iron, zinc, or magnesium ions. These pathologies may include a pathology which is at least partially induced or aggravated by an infectious disease, ...
Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
Zoetis Services Llc
May 18, 2017 - N°20170136117

The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Recombinant rsv reporter virus
Georgia State University And Research Foundation, Inc.
May 11, 2017 - N°20170130279

An rsv reporter strain that can be used for high-throughput drug discovery is disclosed. Also disclosed is a recombinant rsv vector that contains an rsv genome encoding the disclosed rsv reporter strain operably linked to an expression control sequence. Also disclosed is an infectious rsv virion produce by expression of the disclosed recombinant rsv vector in a host cell. Also ...
Prrs viruses, infectious clones, mutants thereof and methods of use
Regents Of The University Minnesota
May 11, 2017 - N°20170130207

This disclosure provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to prrs viruses such as vr-2332, lelystad, or others, and optionally further including a deletion in a region of orf1 that encodes the nsp2 polypeptide.
Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an ...
Assistance Publique Hopitaux De Paris
May 11, 2017 - N°20170128564

The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the human immunodeficiency viruses (hiv) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived ...
Live attenuated classical swine fever vaccine based in genetic manipulation of a putative fusion peptide ...
The United States Of America, As Represented By The Secretary Of Agriculture
May 11, 2017 - N°20170128563

The role of a specific e2 region, 869ckwggnwtcv878, containing a putative fusion peptide (fp) sequence was evaluated. Fps critically contribute to the interaction between proteins and the membrane system of the host cell. Reverse genetics utilizing a full-length infectious clone of the highly virulent csfv strain brescia (bicv) was used to evaluate how amino acid substitutions within this region of ...
Bacteriophage and antibacterial composition comprising the same
Cj Cheiljedang Corporation
May 11, 2017 - N°20170128504

The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising ...
Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive ...
Universite D'aix-marseille
May 11, 2017 - N°20170128433

The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the pp1/gadd34 ...
System and method for preventing transfer of infectious disease
Universite D'aix-marseille
May 04, 2017 - N°20170124850

A system and method to assist in the prevention of the transfer of infectious diseases. More particularly, a system and method that monitors and alerts caregivers to cleanse, sanitize, and/or wash their hands prior to engaging with other individuals in their care. The disclosed technology includes beacons in wireless communication with a mobile computing device, such as a smart ...
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
Immutep
May 04, 2017 - N°20170119876

The present invention relates to the use of a recombinant lag-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
A method for the treatment of glioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from ...
Immutep
May 04, 2017 - N°20170119824

The embodiments of the present invention provide a method for the treatment of glioblastoma using wharton jelly-mesenehmal stem cells (wj-msc) derived from human umbilical cord. The mesenchymal stem cells have potential to inhibit the glioblastoma cancer cells. For isolating the msc, the donor is screened for infectious diseases. The consent from the donor is taken for the collection of the ...
Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
Immutep
May 04, 2017 - N°20170119770

And salts thereof in which r1, r2, r3, r4, x, y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Lanthionine synthetase c-like 2-based therapeutics
Biotherapeutics, Inc.
May 04, 2017 - N°20170119762

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
Compositions comprising peroxyacid and methods for producing and using the same
Chd Bioscience, Inc.
May 04, 2017 - N°20170118991

The present invention provides methods for producing a non α-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods, and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound. In particular, compositions of the ...
Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
Chd Bioscience, Inc.
April 27, 2017 - N°20170114069

And salts thereof in which r1, r2, r3, r4, x, y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Macrocyclic compounds as trk kinase inhibitors
Array Biopharma, Inc.
April 27, 2017 - N°20170114059

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Programmable universal cell receptors and method of using the same
Sorrento Therapeutics, Inc.
April 27, 2017 - N°20170112878

The present invention provides programmable universal cell receptors (pucrs) comprising a catalytic antibody region, a transmembrane domain and a cytoplasmic domain. The pucrs disclosed herein may be conjugated to a specificity agent in order to program the receptor for specificity to any molecule of interest. Also provided are nucleic acids encoding such pucrs, and cells expressing the pucrs. Such cells ...